# Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

> **NCT07239245** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 30 (estimated)

## Conditions studied

- Resectable Hepatocellular Carcinoma With High Risk of Recurrence

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **PROCEDURE:** Transarterial chemoembolization (TACE)

## Key facts

- **NCT ID:** NCT07239245
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-12
- **Primary completion:** 2027-11-10
- **Final completion:** 2030-11-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07239245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07239245, "Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07239245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*